… for mortality among patients treated with carbapenems, β-lactam/β-lactamase inhibitor
combinations (… bacteraemia were eligible. Data were pooled using the technique of meta-analysis. …

… -associated bacteraemia (pooled RR … therapy. Meta-analysis of crude RRs demonstrated
significantly increased incidence of delay in effective therapy in ESBL-associated bacteraemia …

… treatment, and other factors associated with day 30 mortality in patients with bacteremia caused
by extended-spectrum-β-lactamase (… consecutive patients with ESBL bacteremia (due to …

… ever been performed on treatment of bacteremia due to ESBL… of Klebsiella pneumoniae
bacteremia in 12 hospitals in 7 … -day period after onset of bacteremia due to an ESBL-producing …

… be susceptible to β-lactam-β-lactamase inhibitor (… the treatment of bloodstream infections
caused by ESBL producers. We examine why BLBLIs are perceived as inferior in the treatment …

… Mortality and length of hospital stay in patients treated with … empirical therapy cohort (ETC)
and the definitive therapy cohort (… Mortality rates at day 30 for those treated with BLBLI versus …

… with Pitt bacteremia scores of ≥4 who received combination therapy were more … therapy.
The most frequent empirically used beta-lactam antibiotics within 48 h from onset of bacteremia …

… coli bacteraemia, mainly from biliary and urinary sources, did … treated with a carbapenem
and beta-lactam/beta-lactamase … Early appropriate empiric therapy is believed to be critical in …

… and a β-lactam agent for Staphylococcus aureus bacteremia. Vancomycin therapy for …
of empirical vancomycin to definitive β-lactam therapy still appears inferior to initial β-lactam …

… [2] in a prospective study of 10 patients who received treatment for bacteremia caused by
ESBL-producing K. pneumoniae. In all cases, in vitro tests indicated that the infecting strains …